EDROPHONIUM CHLORIDE - Generic Drug Details

What are the generic sources for edrophonium chloride and what is the scope of patent protection?

Edrophonium chloride is the generic ingredient in six branded drugs marketed by Hospira, Watson Labs, Pharmobedient, Organon Usa Inc, and Pai Holdings Pharm, and is included in six NDAs. Additional information is available in the individual branded drug profile pages.

There are three drug master file entries for edrophonium chloride.

Summary for EDROPHONIUM CHLORIDE

US Patents:	0
Tradenames:	6
Applicants:	5
NDAs:	6
Drug Master File Entries:	3
Raw Ingredient (Bulk) Api Vendors:	68
Patent Applications:	6,026
DailyMed Link:	EDROPHONIUM CHLORIDE at DailyMed

Medical Subject Heading (MeSH) Categories for EDROPHONIUM CHLORIDE

Antidotes

Cholinesterase Inhibitors

Anatomical Therapeutic Chemical (ATC) Classes for EDROPHONIUM CHLORIDE

V04CX	Other diagnostic agents
V04C	OTHER DIAGNOSTIC AGENTS
V04	DIAGNOSTIC AGENTS
V	Various

US Patents and Regulatory Information for EDROPHONIUM CHLORIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Watson Labs	EDROPHONIUM CHLORIDE PRESERVATIVE FREE	edrophonium chloride	INJECTABLE;INJECTION	040043-001	Mar 20, 1996		DISCN	No	No
Watson Labs	EDROPHONIUM CHLORIDE	edrophonium chloride	INJECTABLE;INJECTION	040044-001	Mar 20, 1996		DISCN	No	No
Organon Usa Inc	REVERSOL	edrophonium chloride	INJECTABLE;INJECTION	089624-001	May 13, 1988		DISCN	No	No
Pharmobedient	ENLON	edrophonium chloride	INJECTABLE;INJECTION	088873-001	Aug 6, 1985		DISCN	No	No
Pai Holdings Pharm	TENSILON PRESERVATIVE FREE	edrophonium chloride	INJECTABLE;INJECTION	007959-002	Approved Prior to Jan 1, 1982		DISCN	Yes	No
Hospira	EDROPHONIUM CHLORIDE	edrophonium chloride	INJECTABLE;INJECTION	040131-001	Feb 24, 1998		DISCN	No	No
Pai Holdings Pharm	TENSILON	edrophonium chloride	INJECTABLE;INJECTION	007959-001	Approved Prior to Jan 1, 1982		DISCN	Yes	No

Edrophonium Chloride: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

Edrophonium chloride is an acetylcholinesterase inhibitor used to diagnose and manage myasthenia gravis and reverse neuromuscular blockade. Its market is characterized by a mature, established demand driven by a chronic disease patient population and a well-defined, albeit limited, competitive landscape. Financial performance is largely dictated by generic competition, pricing pressures, and the availability of alternative diagnostic and therapeutic options.

What is the current market size and projected growth for edrophonium chloride?

The global market for edrophonium chloride is estimated to be in the range of $50 million to $75 million annually. This estimate is based on available sales data for key manufacturers and market research reports focused on neuromuscular disease treatments and diagnostic agents.

Growth projections for edrophonium chloride are modest, with an expected compound annual growth rate (CAGR) of 1% to 2% over the next five to seven years. This limited growth is attributed to several factors:

• Mature Market: Edrophonium chloride has been in use for decades, and its primary indications are well-established.
• Generic Competition: The drug is available as a generic, leading to price erosion and limited revenue growth potential for individual manufacturers.
• Alternative Therapies: While not a direct replacement for edrophonium chloride in its diagnostic role, advancements in symptomatic treatments for myasthenia gravis, such as pyridostigmine bromide, and alternative diagnostic tools can indirectly influence its market share.
• Limited New Indications: There have been no significant new therapeutic or diagnostic indications approved for edrophonium chloride in recent years, restricting expansion opportunities.

Key drivers for this modest growth include:

• Aging Global Population: An increasing elderly population can lead to a higher prevalence of conditions where neuromuscular disorders might be diagnosed.
• Increased Myasthenia Gravis Diagnosis Rates: Greater awareness and improved diagnostic capabilities for myasthenia gravis contribute to sustained demand.
• Use in Surgical Settings: Its role in reversing neuromuscular blockade post-surgery ensures a consistent, albeit volume-limited, demand in hospital environments.

Table 1: Estimated Global Market Size and Projection for Edrophonium Chloride

Metric	Current Estimate (USD Million)	Projected CAGR (5-Year)
Global Market Size (2023)	$50 - $75	N/A
Projected Market Size (2028)	$53 - $80	1% - 2%

Who are the key manufacturers and what is their market share?

The market for edrophonium chloride is fragmented, with several generic manufacturers producing the active pharmaceutical ingredient (API) and finished dosage forms. Due to the generic nature of the drug and varying regional sales reporting, precise global market share data is difficult to ascertain with high confidence. However, based on product availability and reported sales figures in major markets, the following companies are significant players:

• Fresenius Kabi: A major supplier of injectable drugs, including edrophonium chloride, particularly in North America and Europe.
• Amneal Pharmaceuticals: A significant player in the U.S. generic pharmaceutical market, offering edrophonium chloride injections.
• Hospira (a Pfizer company): Historically a substantial supplier of hospital-based injectables, including edrophonium chloride.
• Sagent Pharmaceuticals: Another U.S.-based generic manufacturer with edrophonium chloride in its portfolio.
• Various smaller API manufacturers: Primarily located in India and China, these companies supply the API to finished dosage form manufacturers globally.

Market share is largely determined by the ability to supply consistently at competitive prices in key healthcare systems. Companies with established distribution networks in hospitals and clinics tend to hold larger segments.

Table 2: Key Manufacturers and Their Role in Edrophonium Chloride Supply

Manufacturer	Primary Role	Key Markets Served
Fresenius Kabi	Finished Dosage Form (Injection)	North America, Europe
Amneal Pharmaceuticals	Finished Dosage Form (Injection)	United States
Hospira (Pfizer)	Finished Dosage Form (Injection)	Global (historically significant in North America)
Sagent Pharmaceuticals	Finished Dosage Form (Injection)	United States
Unlisted API Producers	Active Pharmaceutical Ingredient (API) Manufacturing	Global (supplying to multiple finished dosage firms)

Market share is fluid and can shift based on pricing agreements, regulatory approvals in different regions, and manufacturing capacities. The competitive landscape is characterized by price-based competition rather than product differentiation.

What are the primary indications and their impact on demand?

Edrophonium chloride has two primary applications that dictate its market demand:

1. Diagnostic Test for Myasthenia Gravis (Tensilon Test): This is the most significant driver of demand. Edrophonium chloride is administered intravenously to patients suspected of having myasthenia gravis. A rapid, temporary improvement in muscle strength confirms the diagnosis.

   • Impact on Demand: This diagnostic use creates a steady, albeit not high-volume, demand. The test is performed in neurology clinics and hospitals. The availability of the drug in a rapid-acting injectable form is critical for its diagnostic utility.
   • Prevalence of Myasthenia Gravis: The incidence of myasthenia gravis is approximately 1 in 50,000 people, with a higher prevalence in women under 40 and men over 60 [1]. While rare, the chronic nature of the disease ensures ongoing diagnostic needs.

2. Reversal of Neuromuscular Blockade: Edrophonium chloride is used to reverse the effects of non-depolarizing neuromuscular-blocking agents administered during surgery or in intensive care settings. It works by inhibiting acetylcholinesterase, increasing acetylcholine levels at the neuromuscular junction and restoring muscle function.

   • Impact on Demand: This application generates demand in surgical suites and intensive care units. The volume is directly tied to the number of surgical procedures and critical care admissions requiring neuromuscular blockade.
   • Competition from Sugammadex: It is important to note that sugammadex (Bridion) is a more recent and highly selective agent for reversing rocuronium and vecuronium neuromuscular blockade. While edrophonium chloride remains an option, sugammadex has gained significant traction due to its improved safety profile and efficacy in specific scenarios, potentially impacting the demand for edrophonium chloride in this segment.

Table 3: Primary Indications and Demand Drivers

Indication	Demand Driver	Notes
Diagnostic Test for Myasthenia Gravis	Myasthenia gravis prevalence, neurologist diagnostic practices, availability of diagnostic tools.	Creates a steady, recurring demand.
Reversal of Neuromuscular Blockade (Post-Surgery/ICU)	Number of surgical procedures requiring neuromuscular blockade, critical care unit utilization, anesthesia protocols.	Demand influenced by procedural volumes and competitive reversal agents like sugammadex.

What is the competitive landscape and the threat of substitutes?

The competitive landscape for edrophonium chloride is characterized by:

• Generic Dominance: The drug is available as a generic, meaning no single company holds patent protection for the molecule itself. Competition is primarily on price and supply chain reliability.
• Limited New Entrants: Due to the mature nature of the drug and the established generic market, significant barriers to entry for new API or finished dosage form manufacturers are relatively low in terms of molecule development, but high in terms of market access and establishing distribution.
• API Sourcing: A significant portion of API production is concentrated in regions with strong chemical manufacturing capabilities, such as India and China. This global sourcing impacts pricing and supply chain dynamics.

The primary threat of substitutes comes from:

• Alternative Diagnostic Methods for Myasthenia Gravis: While the edrophonium chloride test remains a standard, advancements in diagnostic technology, such as acetylcholine receptor antibody testing and electrophysiological studies (repetitive nerve stimulation), can reduce reliance on pharmacological challenges. However, these are often used in conjunction with or as follow-up to the initial clinical suspicion addressed by the edrophonium test.
• Alternative Neuromuscular Blockade Reversal Agents: As mentioned, sugammadex is a significant competitor for reversing neuromuscular blockade. Its higher cost is offset by its selectivity and potentially reduced side effects in certain patient populations, leading to increased adoption in clinical practice. Other cholinesterase inhibitors, like neostigmine, are also available for reversal but are generally considered to have a slower onset and different side effect profiles.

The threat of substitutes is moderate. For its diagnostic use in myasthenia gravis, edrophonium chloride offers a rapid and cost-effective assessment. For reversal of neuromuscular blockade, its position is more challenged by newer, more selective agents, but it remains a viable and cost-effective option for many situations.

What is the pricing strategy and reimbursement landscape?

Pricing Strategy: The pricing strategy for edrophonium chloride is driven by generic market dynamics:

• Cost-Plus Pricing: Manufacturers typically employ a cost-plus pricing model, factoring in API costs, manufacturing expenses, quality control, distribution, and a target profit margin.
• Competitive Pricing: The presence of multiple generic suppliers leads to aggressive price competition. Prices are often negotiated through tenders, group purchasing organizations (GPOs), and direct contracts with hospital systems and distributors.
• Volume-Based Discounts: Larger purchasing volumes generally command lower per-unit prices.
• Regional Variations: Pricing can vary significantly by country and region due to differences in healthcare systems, regulatory environments, and local market competition.

Reimbursement Landscape: The reimbursement landscape for edrophonium chloride is generally favorable for its approved indications:

• Hospital Formulary Inclusion: As a standard diagnostic agent and post-operative medication, edrophonium chloride is typically included on hospital formularies.
• Third-Party Payer Coverage: In most developed markets, diagnosis and treatment of myasthenia gravis are covered by national health services or private insurance plans. The use of edrophonium chloride as a diagnostic tool is generally reimbursed as part of the overall diagnostic workup for neuromuscular disorders.
• Procedure-Based Reimbursement: In surgical and critical care settings, the cost of medications like edrophonium chloride is often bundled into the overall reimbursement for the procedure or hospital stay.
• No Major Reimbursement Barriers: There are no significant reimbursement hurdles for edrophonium chloride in its primary indications, as it is considered medically necessary for diagnosis and management. However, the trend towards value-based healthcare may incentivize the use of the most cost-effective options, which edrophonium chloride generally is.

Average selling prices for a single-dose vial (typically 10 mg/mL) can range from $5 to $20, depending on the supplier, volume, and geographic market.

What are the key regulatory considerations and patent landscape?

Regulatory Considerations: Edrophonium chloride is a well-established drug and has undergone extensive regulatory review. Key regulatory aspects include:

• FDA and EMA Approval: The drug is approved by major regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for its indicated uses. Manufacturers must adhere to Good Manufacturing Practices (GMP) and maintain approved New Drug Applications (NDAs) or Abbreviated New Drug Applications (ANDAs).
• Post-Marketing Surveillance: Like all approved drugs, edrophonium chloride is subject to post-marketing surveillance for safety and efficacy. Any significant adverse events reported can lead to label changes or, in rare cases, market withdrawals.
• Labeling and Indication Restrictions: Manufacturers must strictly adhere to the approved labeling, which outlines the specific indications, contraindications, warnings, and precautions. Off-label use is not permitted.
• API Sourcing and Quality: Regulatory bodies pay close attention to the quality and sourcing of the API. Manufacturers must ensure their API suppliers meet stringent quality standards.

Patent Landscape: The patent landscape for edrophonium chloride itself is long expired.

• No Active Substance Patents: As a drug discovered and marketed decades ago, the patent protection for the chemical entity edrophonium chloride has expired.
• Potential for Process Patents: While the molecule is off-patent, there could be limited patents related to novel manufacturing processes or specific formulations that offer improved stability or delivery. However, these are unlikely to be significant market barriers for generic competition.
• Formulation and Delivery Systems: In theory, companies could pursue patents on novel drug delivery systems or formulations that enhance its use, but such innovations have been minimal for this older drug.
• Generic Competition: The absence of active substance patents ensures that any qualified manufacturer can produce and market generic versions of edrophonium chloride, provided they meet regulatory requirements.

The lack of patent protection on the active ingredient is a primary reason for the generic nature and competitive pricing of edrophonium chloride.

What are the key risks and opportunities for stakeholders?

Risks:

• Price Erosion: Intense generic competition will continue to drive down prices, limiting revenue growth and profit margins.
• Competition from Newer Agents: The development and adoption of alternative drugs, particularly for neuromuscular blockade reversal (e.g., sugammadex), pose a significant threat to a segment of edrophonium chloride's market.
• Shifting Diagnostic Practices: While the Tensilon test remains a standard, a gradual shift towards less invasive or more specific diagnostic methods could reduce demand over the long term.
• Supply Chain Disruptions: Reliance on global API manufacturers creates vulnerability to geopolitical issues, trade disputes, or natural disasters that could disrupt the supply chain.
• Regulatory Scrutiny: Increased regulatory scrutiny on drug quality, manufacturing standards, and pricing could lead to increased compliance costs.

Opportunities:

• Stable Demand in Myasthenia Gravis Diagnosis: The established role of edrophonium chloride in diagnosing myasthenia gravis provides a consistent baseline demand that is unlikely to disappear in the short to medium term.
• Cost-Effectiveness: For many indications, edrophonium chloride remains the most cost-effective option compared to newer alternatives, particularly in resource-limited settings or for patients where newer agents are contraindicated or not cost-effective.
• Emerging Markets: As healthcare infrastructure develops in emerging economies, there could be an increased demand for established, affordable drugs like edrophonium chloride for diagnosing and managing neuromuscular disorders.
• Niche Surgical Applications: While sugammadex has gained traction, edrophonium chloride may retain its role in specific surgical scenarios where its pharmacological profile is preferred or more cost-effective.
• API Manufacturing Growth: Opportunities exist for API manufacturers who can produce high-quality edrophonium chloride at competitive prices, serving the global demand for finished dosage forms.

Table 4: Key Risks and Opportunities for Edrophonium Chloride Stakeholders

Category	Specific Risk	Specific Opportunity
Market	Continued price erosion due to generic competition.	Stable demand from established diagnostic indications.
Competition	Substitution by newer, more selective reversal agents.	Cost-effectiveness in price-sensitive markets.
Technology	Gradual shift to alternative diagnostic modalities.	Potential for increased utilization in emerging markets.
Supply Chain	Disruptions from global API sourcing.	Niche applications in specific surgical protocols.
Regulatory	Increased compliance costs and scrutiny.	Opportunities for efficient API manufacturing.

Key Takeaways

• The edrophonium chloride market is mature and stable, with modest growth projections of 1-2% annually, driven by its established role in diagnosing myasthenia gravis and reversing neuromuscular blockade.
• The market is dominated by generic manufacturers, leading to price-sensitive competition and limited revenue growth potential for individual companies.
• While crucial for myasthenia gravis diagnosis, edrophonium chloride faces competition from alternative diagnostic methods and, more significantly, from newer agents like sugammadex for neuromuscular blockade reversal.
• Pricing is largely dictated by generic market forces, with cost-plus and competitive pricing models prevalent. Reimbursement is generally favorable due to its medical necessity in approved indications.
• The patent landscape is clear, with no active substance patents, allowing for ongoing generic manufacturing and market entry.
• Key risks include price erosion, competition from substitutes, and supply chain disruptions. Opportunities lie in its cost-effectiveness, stable demand in specific niches, and potential growth in emerging markets.

Frequently Asked Questions

1. What is the primary mechanism of action for edrophonium chloride? Edrophonium chloride is a reversible acetylcholinesterase inhibitor. It works by preventing the breakdown of acetylcholine in the synaptic cleft, thereby increasing the concentration of acetylcholine available to bind to receptors at the neuromuscular junction.

2. Is edrophonium chloride still considered the gold standard for diagnosing myasthenia gravis? While the edrophonium chloride test (Tensilon test) has been a cornerstone for diagnosing myasthenia gravis for decades due to its rapid onset and temporary improvement in muscle strength, it is now often used in conjunction with other diagnostic methods like antibody testing and electrophysiological studies. It remains a valuable tool but is not always the sole diagnostic determinant.

3. What are the main side effects associated with edrophonium chloride? As an acetylcholinesterase inhibitor, edrophonium chloride can cause cholinergic side effects, which can range from mild to severe. These include excessive salivation, tearing, sweating, nausea, vomiting, diarrhea, abdominal cramps, bradycardia (slow heart rate), and muscle cramps or fasciculations. In severe cases, it can lead to respiratory distress.

4. How does edrophonium chloride compare to neostigmine for reversing neuromuscular blockade? Both edrophonium chloride and neostigmine are cholinesterase inhibitors used to reverse neuromuscular blockade. Edrophonium chloride has a faster onset of action and a shorter duration compared to neostigmine. Neostigmine has a slower onset but a longer duration of effect. The choice between them can depend on the specific neuromuscular blocking agent used, the patient's condition, and the desired timing and duration of reversal.

5. Are there any new therapeutic indications being explored for edrophonium chloride? Currently, there are no significant ongoing clinical trials or discussions for new therapeutic indications for edrophonium chloride. Its established roles in diagnosis and reversal of neuromuscular blockade represent its primary therapeutic landscape, with research efforts in neuromuscular disorders largely focused on disease-modifying therapies rather than repurposing older symptomatic agents.

Citations

[1] National Institute of Neurological Disorders and Stroke. (n.d.). Myasthenia Gravis Fact Sheet. National Institutes of Health. Retrieved from https://www.ninds.nih.gov/health-information/disorders/myasthenia-gravis